Therapeutic Plasma Exchange in the Management of Myasthenia Crisis in a Resource Poor Setting

Akingbola T. S., Shonde-Adebola K. B., Anyanwu-Yeiya C. C., Ezekekwu C. A., Adeoye O. A., Odebiyi H. A., Akinyemi R. and Kotila T. R.
Additional contact information
Akingbola T. S.: Department of Haematology University College Hospital (UCH), Ibadan Oyo state Nigeria, Nigeria
Shonde-Adebola K. B.: Department of Haematology University College Hospital (UCH), Ibadan Oyo state Nigeria, Nigeria
Anyanwu-Yeiya C. C.: Department of Haematology University College Hospital (UCH), Ibadan Oyo state Nigeria, Nigeria
Ezekekwu C. A.: Department of Haematology University College Hospital (UCH), Ibadan Oyo state Nigeria, Nigeria
Adeoye O. A.: Department of Haematology University College Hospital (UCH), Ibadan Oyo state Nigeria, Nigeria
Odebiyi H. A.: Department of Haematology University College Hospital (UCH), Ibadan Oyo state Nigeria, Nigeria
Akinyemi R.: Department of internal Medicine (Neurology Unit) UCH, Ibadan, Oyo state Nigeria, Nigeria
Kotila T. R.: Department of Haematology University College Hospital (UCH), Ibadan Oyo state Nigeriak, Nigeria

International Journal of Healthcare and Medical Sciences, 2019, vol. 5, issue 5, 22-25

Abstract: BACKGROUND: Therapeutic Plasma Exchange (TPE) is an apheresis treatment in which the plasma component of blood is removed and replaced with supplemental fluids. It is an immunomodulatory treatment that has been reported to be a successful therapeutic procedure for the treatment of severely compromised patients with myasthenia gravis when given at short intervals. TPE is known to have a comparable efficacy to intravenous immunoglobulin (IVIG) in the treatments of patients with moderate to severe myasthenia crisis. METHODOLOGY: We report a case of a 47year old male patient with severe myasthenia crisis. He was managed using cobe spectra version 6.1 to carry out an automated TPE, with a suboptimal response and subsequent use of IVIG resulting in full recovery. This report highlights the possible factors that may hinder optimal response of a patient with Myasthenia crisis to TPE procedure in a poor resource setting. CONCLUSION: TPE is an essential immunomodulatory therapy in the management of acute myasthenia crisis whether given alone or in combination with immunosuppressive drugs. There can be a rebound overproduction of the offending autoantibodies in MG following TPE which can be cleared from circulation using immunosuppressive therapy.

Keywords: Myasthenia gravis; Myasthenia crisis; Therapeutic plasma exchange; Challenges. (search for similar items in EconPapers)
Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.arpgweb.com/pdf-files/ijhms5(5)22-25.pdf (application/pdf)
https://www.arpgweb.com/journal/13/archive/05-2019/5/5 (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:arp:ijohms:2019:p:22-25

DOI: 10.32861/ijhms.55.22.25

Access Statistics for this article

International Journal of Healthcare and Medical Sciences is currently edited by Dr. Bonyah, Ebenezer

More articles in International Journal of Healthcare and Medical Sciences from Academic Research Publishing Group Rahim Yar Khan 64200, Punjab, Pakistan.
Bibliographic data for series maintained by Managing Editor ().